OncoMatch/Clinical Trials/NCT05963347
Go-CHOP as the Frontline Therapy for PTCL
Is NCT05963347 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Golidocitinib and CHOP Regimen for peripheral t cell lymphoma.
Treatment: Golidocitinib · CHOP Regimen — This is a phase 2 Study to investigate the safety, tolerability, and anti-tumor activity of golidocitinib in Combination with CHOP as the front-line Treatment for Participants with Peripheral T-cell Lymphomas (PTCL).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic anti-lymphoma therapy
Exception: short-term corticosteroids (duration ≤ 7 days, equivalent prednisone dose ≤ 15 mg/day)
Prior therapy for PTCL prior to enrollment, except short-term corticosteroids (duration ≤ 7 days, equivalent prednisone dose ≤ 15 mg/day)
Cannot have received: radiation therapy
Exception: local therapy for individual areas
Prior radiation therapy for PTCL except local therapy for individual areas
Cannot have received: systemic antineoplastic or investigational therapy
Currently receiving other systemic antineoplastic or investigational therapy
Cannot have received: anthracycline/anthraquinone (doxorubicin, epirubicin, daunorubicin, mitoxantrone)
Participants who have received more than 200 mg/m2 doxorubicin or other equivalent doses of anthracycline/anthraquinone (e.g., epirubicin, daunorubicin, mitoxantrone, etc.) cumulatively
Cannot have received: JAK inhibitor
Prior treatment with JAK or STAT3 inhibitors following diagnosis of PTCL
Cannot have received: live vaccine
Live vaccine within 28 days prior to enrollment
Lab requirements
Blood counts
adequate bone marrow reserve
Kidney function
adequate organ system function reserve
Liver function
adequate organ system function reserve
Cardiac function
Left ventricular ejection fraction (LVEF) ≥ 50% as assessed by ECHO
Adequate bone marrow reserve and organ system function reserve. Left ventricular ejection fraction (LVEF) ≥ 50% as assessed by ECHO.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify